Treatment of Helicobacter pylori

Publisher Website
Google Scholar
Abstract
Helicobacter pylori is the most common infection in the world and is associated with some of the most prevelent gastroduodenal pathologies. There is now considerable evidence that H. pylori eradication not only heals duodenal ulcers, but also prevents ulser recurrences and probably ulcer complication. It is, therefore universally accepted that all patient with duodenal ulcers should recieve eradication therapy. This review represent attempt to summarize and analyse all the studies publised from March 1997 to March 1998, in which different anti-H.pylori regimens have been used. Despite a large number of clinical trials (51), no significant advances have been made in H.pyloritherapy so the optimal eradication treatment still remain a matter of debate.More than 6000 patient were treated in these studies and most (around 5000) were found to have a peptiuc ulcer disease; this represents no more than 10-15% of our endoscopic findings. Eleven studies addressed the non-ulcer dyspepsia debtate (less than 1000 patients). These studies did not define the best therapy or the benifit of treatment. the prompt pump inhibitor regimens are definitely the most repsentative drug policy to have appeared in the litreture; despite several attempts (proton pump inhibitor treatment given for less than 1 week, for 1 week, or for more than 1 week ) the short 1-week regimen recommendation has been recognised as the most promising treatment. what has been highlighted is the importance of imidazole-resistant and -sensitive strains when considering the eradication rate.

This publication has 0 references indexed in Scilit: